Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
BSTC's Cash to Debt is ranked higher than
87% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. BSTC: No Debt )
BSTC' s 10-Year Cash to Debt Range
Min: 0.06   Max: No Debt
Current: No Debt

Equity to Asset 0.96
BSTC's Equity to Asset is ranked higher than
98% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. BSTC: 0.96 )
BSTC' s 10-Year Equity to Asset Range
Min: -5.34   Max: 0.96
Current: 0.96

-5.34
0.96
Interest Coverage No Debt
BSTC's Interest Coverage is ranked higher than
83% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BSTC: No Debt )
BSTC' s 10-Year Interest Coverage Range
Min: 80.45   Max: 9999.99
Current: No Debt

80.45
9999.99
F-Score: 5
Z-Score: 143.01
M-Score: -2.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 50.06
BSTC's Operating margin (%) is ranked higher than
98% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. BSTC: 50.06 )
BSTC' s 10-Year Operating margin (%) Range
Min: -296.7   Max: 54.91
Current: 50.06

-296.7
54.91
Net-margin (%) 33.54
BSTC's Net-margin (%) is ranked higher than
96% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. BSTC: 33.54 )
BSTC' s 10-Year Net-margin (%) Range
Min: -300.13   Max: 63.95
Current: 33.54

-300.13
63.95
ROE (%) 19.23
BSTC's ROE (%) is ranked higher than
94% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. BSTC: 19.23 )
BSTC' s 10-Year ROE (%) Range
Min: -343.89   Max: 61.21
Current: 19.23

-343.89
61.21
ROA (%) 18.35
BSTC's ROA (%) is ranked higher than
97% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. BSTC: 18.35 )
BSTC' s 10-Year ROA (%) Range
Min: -156.91   Max: 53.14
Current: 18.35

-156.91
53.14
ROC (Joel Greenblatt) (%) 180.87
BSTC's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. BSTC: 180.87 )
BSTC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -406600   Max: 275.15
Current: 180.87

-406600
275.15
Revenue Growth (%) 32.40
BSTC's Revenue Growth (%) is ranked higher than
93% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BSTC: 32.40 )
BSTC' s 10-Year Revenue Growth (%) Range
Min: -47   Max: 65.8
Current: 32.4

-47
65.8
» BSTC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BSTC Guru Trades in Q3 2013

Jim Simons 31,745 sh (New)
Chuck Royce 100,000 sh (unchged)
» More
Q4 2013

BSTC Guru Trades in Q4 2013

Chuck Royce 100,000 sh (unchged)
Jim Simons 15,800 sh (-50.23%)
» More
Q1 2014

BSTC Guru Trades in Q1 2014

Chuck Royce 100,000 sh (unchged)
Jim Simons 14,900 sh (-5.7%)
» More
Q2 2014

BSTC Guru Trades in Q2 2014

Jim Simons 67,009 sh (+349.72%)
Chuck Royce 100,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BSTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 58.30
BSTC's P/E(ttm) is ranked higher than
88% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BSTC: 58.30 )
BSTC' s 10-Year P/E(ttm) Range
Min: 14.34   Max: 109.97
Current: 58.3

14.34
109.97
P/B 9.40
BSTC's P/B is ranked higher than
65% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. BSTC: 9.40 )
BSTC' s 10-Year P/B Range
Min: 4.65   Max: 525
Current: 9.4

4.65
525
P/S 19.60
BSTC's P/S is ranked higher than
73% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.28 vs. BSTC: 19.60 )
BSTC' s 10-Year P/S Range
Min: 2.57   Max: 75
Current: 19.6

2.57
75
PFCF 53.00
BSTC's PFCF is ranked higher than
93% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BSTC: 53.00 )
BSTC' s 10-Year PFCF Range
Min: 1.13   Max: 3172
Current: 53

1.13
3172
EV-to-EBIT 33.27
BSTC's EV-to-EBIT is ranked higher than
90% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BSTC: 33.27 )
BSTC' s 10-Year EV-to-EBIT Range
Min: 13.4   Max: 63.9
Current: 33.27

13.4
63.9
Shiller P/E 91.10
BSTC's Shiller P/E is ranked higher than
93% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BSTC: 91.10 )
BSTC' s 10-Year Shiller P/E Range
Min: 66.64   Max: 2000
Current: 91.1

66.64
2000
Current Ratio 23.49
BSTC's Current Ratio is ranked higher than
97% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. BSTC: 23.49 )
BSTC' s 10-Year Current Ratio Range
Min: 0.43   Max: 23.49
Current: 23.49

0.43
23.49
Quick Ratio 23.49
BSTC's Quick Ratio is ranked higher than
97% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. BSTC: 23.49 )
BSTC' s 10-Year Quick Ratio Range
Min: 0.41   Max: 23.49
Current: 23.49

0.41
23.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.70
BSTC's Price/Net Cash is ranked higher than
82% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 100.00 vs. BSTC: 14.70 )
BSTC' s 10-Year Price/Net Cash Range
Min: 2.84   Max: 133.33
Current: 14.7

2.84
133.33
Price/Net Current Asset Value 13.40
BSTC's Price/Net Current Asset Value is ranked higher than
80% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 45.54 vs. BSTC: 13.40 )
BSTC' s 10-Year Price/Net Current Asset Value Range
Min: 1.56   Max: 52.5
Current: 13.4

1.56
52.5
Price/Tangible Book 9.60
BSTC's Price/Tangible Book is ranked higher than
71% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. BSTC: 9.60 )
BSTC' s 10-Year Price/Tangible Book Range
Min: 0.59   Max: 425
Current: 9.6

0.59
425
Price/DCF (Projected) 5.30
BSTC's Price/DCF (Projected) is ranked higher than
92% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BSTC: 5.30 )
BSTC' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 733.75
Current: 5.3

0.65
733.75
Price/Median PS Value 1.50
BSTC's Price/Median PS Value is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. BSTC: 1.50 )
BSTC' s 10-Year Price/Median PS Value Range
Min: 0.05   Max: 4.51
Current: 1.5

0.05
4.51
Price/Graham Number 4.80
BSTC's Price/Graham Number is ranked higher than
89% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BSTC: 4.80 )
BSTC' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 8.67
Current: 4.8

0.86
8.67
Earnings Yield (Greenblatt) 3.00
BSTC's Earnings Yield (Greenblatt) is ranked higher than
69% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. BSTC: 3.00 )
BSTC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 7.4
Current: 3

1.6
7.4
Forward Rate of Return (Yacktman) -0.32
BSTC's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. BSTC: -0.32 )
BSTC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.6   Max: -0.2
Current: -0.32

-1.6
-0.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NONOF, AMGN, GILD, BIIB, CELG » details
BioSpecifics Technologies Corp. was incorporated in Delaware in 1990. The Company, a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase under the brand XIAFLEX for clinical indications in Dupuytrens contracture, Peyronies disease, and frozen shoulder. The XIAFLEX is under food and drug administration for the treatment of Dupuytrens contracture; Phase III clinical trials for the treatment of Peyronies disease; phase IIb clinical trials for the nonsurgical treatment of Peyronies disease; Phase IIa clinical trials for the treatment of frozen shoulder syndrome; Phase II trials for the treatment of human lipoma; and Phase Ib clinical trials to treat cellulite. The company also focuses on the development of collagenase for various other clinical indications, including canine lipoma, as well as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications.
» More Articles for BSTC

Headlines

Articles On GuruFocus.com
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 09 2010 
BioSpecifics Technologies Corp. Reports Operating Results (10-Q) Aug 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-03-31 Jan 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-06-30 Jan 13 2009 
BioSpecifics Technologies Corp. Reports Operating Results for Fiscal Quarter Ended on 2008-09-30 Jan 13 2009 
BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market Jan 06 2009 

More From Other Websites
BioSpecifics Technologies Corp. Announces Presentation of Encouraging Preclinical Data for CCH from... Oct 16 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 16 2014
BioSpecifics Technologies Corp. Announces Presentation of Encouraging Preclinical Data for CCH from... Oct 16 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Change in Directors or Principal Officers,... Oct 08 2014
BioSpecifics Technologies Corp. Announces Sudden Passing of Director Max Link, Ph.D. Oct 08 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 19 2014
BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech... Sep 19 2014
BioSpecifics Technologies Corp. Announces New MULTICORD and Retreatment Data for XIAFLEX® for... Sep 18 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Sep 11 2014
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences Sep 02 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... Aug 27 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 22 2014
BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of... Aug 21 2014
BIOSPECIFICS TECHNOLOGIES CORP Financials Aug 19 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results Aug 11 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 08 2014
BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment... Aug 08 2014
BIOSPECIFICS TECHNOLOGIES CORP Files SEC form 8-K, Change in Directors or Principal Officers,... Aug 05 2014
BioSpecifics Technologies Corp. Announces Appointment of Max Link, Ph.D. to Board of Directors Aug 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK